<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323567</url>
  </required_header>
  <id_info>
    <org_study_id>Silesian UM</org_study_id>
    <nct_id>NCT03323567</nct_id>
  </id_info>
  <brief_title>A Comparison of Collagen, Lidocaine and Saline, in Trigger Points in Masseter Muscle.</brief_title>
  <official_title>A Comparison of Collagen, Lidocaine and Saline Intramuscular Injections, in Myofascial Pain Patients With Trigger Points in Masseter Muscle.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An intramusclular injection of three solutions were performed( collagen, lidocaine, saline)
      in musculoskeletal trigger points, in patients suffering from temporomandibular
      disorders(TMD). Best results were observed in collagen group: reduction of 59,2% sEMG
      activity of masseter muscles and 53,75% reduction of pain intensity in VAS scale.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collagen is an important component, building myocytes and extracellular matrix of skeletal
      muscles. The novel treatment option for trigger point therapy and muscle regeneration in TMD
      patients are intramuscular collagen injections. The aim of the study was to evaluate the
      efficacy of intramuscular injections of Collagen MD Muscle(Guna) 2 ml, 2 ml of Lidocainum 2%
      without vasoconstrictor and 2 ml of Saline (0,9 % NaCl). 43 patients were enrolled to the
      study (17 male and 26 female, 40 +/- 3,8 years old). The masseter muscle activity was
      measured with sEMG Neurobit Optima 4 (Neurobit System). Visual Analogue Scale was used to
      determine pain intensity changes between follow-up visits in each group. Trigger points were
      localized with palpation of masseter muscle. Electromyographic activity of masseter muscle
      was measured before injections on each visit: 0, 7,14 days. In our analysis sEMG masseter
      muscle activity was significantly decreased: in collagen group 59,2%, in lidocainum group
      39,3% and in saline group14%. Pain intensity reduction in VAS scale was 53,75% in collagen
      group, in lidocainum group 25% and in saline group 20,1%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 10, 2016</start_date>
  <completion_date type="Actual">October 12, 2017</completion_date>
  <primary_completion_date type="Actual">October 4, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>patients were divided into the three groups and examination and therapy was performed after 7 and 14 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Participants and care providers had no knowledge about the substance prepared for the injection. The information for the main investigator was the number of patient and the number of injection</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>sEMG reduction of masseter muscle in TMD patients</measure>
    <time_frame>14 days</time_frame>
    <description>reduction of electromyograpic activity of masseter muscle</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Temporomandibular Disorder</condition>
  <arm_group>
    <arm_group_label>MD Muscle Collagen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group with collagen intramuscular injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine 2% group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group with 2% Lidocaine intramuscular injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group with 0,9% NaCl intramuscular injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MD Muscle GUNA collagen</intervention_name>
    <description>intramusclular injections of MD Muscle collagen</description>
    <arm_group_label>MD Muscle Collagen group</arm_group_label>
    <other_name>intramuscular MD Muscle collagen injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 2% Injectable Solution</intervention_name>
    <description>intramuscular Lidocaine 2% injection</description>
    <arm_group_label>Lidocaine 2% group</arm_group_label>
    <other_name>intramuscular Lidocaine 2% injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution, Hypertonic</intervention_name>
    <description>intramuscular Saline injection</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>intramuscular Saline injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - sleep bruxism, DC/TMD myofascial pain, myofascial pain with referral

        Exclusion Criteria:

          -  younger than 18years old, active orthodonctic treatment,neurological treatment, post
             radiotherapy, after head trauma within 2 years, patients with unsupported occlusal
             contacts, addicted to analgesic drugs, with the fear of needle
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of TMD and Orthodontics Silesian Medical University</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Turo D, Otto P, Hossain M, Gebreab T, Armstrong K, Rosenberger WF, Shao H, Shah JP, Gerber LH, Sikdar S. Novel Use of Ultrasound Elastography to Quantify Muscle Tissue Changes After Dry Needling of Myofascial Trigger Points in Patients With Chronic Myofascial Pain. J Ultrasound Med. 2015 Dec;34(12):2149-61. doi: 10.7863/ultra.14.08033. Epub 2015 Oct 21.</citation>
    <PMID>26491094</PMID>
  </reference>
  <reference>
    <citation>JÃ¤rvholm U, Palmerud G, Styf J, Herberts P, Kadefors R. Intramuscular pressure in the supraspinatus muscle. J Orthop Res. 1988;6(2):230-8.</citation>
    <PMID>3343629</PMID>
  </reference>
  <reference>
    <citation>Lehto M, Sims TJ, Bailey AJ. Skeletal muscle injury--molecular changes in the collagen during healing. Res Exp Med (Berl). 1985;185(2):95-106.</citation>
    <PMID>3992061</PMID>
  </reference>
  <reference>
    <citation>Sorichter S, Mair J, Koller A, Gebert W, Rama D, Calzolari C, Artner-Dworzak E, Puschendorf B. Skeletal troponin I as a marker of exercise-induced muscle damage. J Appl Physiol (1985). 1997 Oct;83(4):1076-82.</citation>
    <PMID>9338413</PMID>
  </reference>
  <reference>
    <citation>Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J Cell Sci. 2015 Oct 1;128(19):3525-31. doi: 10.1242/jcs.169748. Epub 2015 Sep 16. Review.</citation>
    <PMID>26377767</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Aleksandra Nitecka-Buchta</investigator_full_name>
    <investigator_title>Principal Investigator D.M.D. PhD</investigator_title>
  </responsible_party>
  <keyword>TMD, collagen, intramuscular injection, trigger point</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

